Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8673 - 8680 of 12086 results
Political Agreement Reached on US-EU Safe Harbor; Details "Hazy"
February 2, 2016| Blog| Viewpoint
Mintz Launches Sports-Focused Practice Group
February 2, 2016| News
Provider Consolidation: Prescription for Surviving Antitrust Investigations
February 2, 2016| News
Preparation for 2015 Fiscal Year-End SEC Filings and 2016 Annual Shareholder Meetings
February 2, 2016| Advisory| Viewpoint
DOL Issues Guidance on Joint Employment
February 1, 2016| Blog| Viewpoint
Governor Baker Files FY2017 Budget, Economic Development Bill; Speaker DeLeo Outlines Agenda
February 1, 2016| Alert| Viewpoint
FDA Releases Draft Guidance for Medical Device Cybersecurity
February 1, 2016| Blog| Viewpoint
Inphi v. Netlist: Alternative Features Satisfy the Patent Written Description Requirement for a Negative Claim Limitation
February 1, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|